ES2173923T3 - Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente. - Google Patents

Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente.

Info

Publication number
ES2173923T3
ES2173923T3 ES94928864T ES94928864T ES2173923T3 ES 2173923 T3 ES2173923 T3 ES 2173923T3 ES 94928864 T ES94928864 T ES 94928864T ES 94928864 T ES94928864 T ES 94928864T ES 2173923 T3 ES2173923 T3 ES 2173923T3
Authority
ES
Spain
Prior art keywords
pct
polyether
agent
polieter
inactivate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94928864T
Other languages
English (en)
Inventor
Johann Eibl
Friedrich Dorner
Noel Barrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4434538A external-priority patent/DE4434538C2/de
Application filed by Baxter AG filed Critical Baxter AG
Application granted granted Critical
Publication of ES2173923T3 publication Critical patent/ES2173923T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

LA INVENCION DESCRIBE UNA PREPARACION FARMACEUTICA CONTENIENDO UNA PROTEINA PLASMATICA, ESTANDO ESTA PREPARACION LIBRE DE AGENTES INFECCIOSOS Y BASTANTE LIBRE DE PRODUCTOS DESNATURALIZANTES. SE OBTIENE POR UN PROCEDIMIENTO CON LAS SIGUIENTES ETAPAS: A) ADICION DE UN POLIETER A LA SOLUCION QUE CONTIENE LA PROTEINA PLASMATICA CON POSIBLE LIOFILIZACION DE LA SOLUCION; B) DESACTIVACION DE AGENTES INFECCIOSOS EN PRESENCIA DEL POLIETER POR UN TRATAMIENTO FISICO-QUIMICO O QUIMICO; Y C) RETIRADA DEL POLIETER.
ES94928864T 1993-10-06 1994-10-06 Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente. Expired - Lifetime ES2173923T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4334087 1993-10-06
DE4434538A DE4434538C2 (de) 1993-10-06 1994-09-27 Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens

Publications (1)

Publication Number Publication Date
ES2173923T3 true ES2173923T3 (es) 2002-11-01

Family

ID=25930216

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94928864T Expired - Lifetime ES2173923T3 (es) 1993-10-06 1994-10-06 Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente.

Country Status (12)

Country Link
US (1) US5770199A (es)
EP (1) EP0722344B1 (es)
JP (1) JPH09503218A (es)
AT (1) ATE211927T1 (es)
CA (1) CA2173625A1 (es)
CZ (1) CZ95296A3 (es)
DK (1) DK0722344T3 (es)
ES (1) ES2173923T3 (es)
FI (1) FI961536A0 (es)
HR (1) HRP940645A2 (es)
HU (1) HU218490B (es)
WO (1) WO1995009657A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301921A1 (en) * 1997-08-20 1999-02-25 John Graham Goddard Compositions containing polyethylene glycol and uses thereof
US6078119A (en) * 1997-11-26 2000-06-20 Ebara Corporation Bearingless rotary machine
AUPP276098A0 (en) * 1998-04-01 1998-04-30 Nokuta Pty Ltd A method for treating gelatine
DE60027695T2 (de) * 1999-02-12 2007-04-26 Baxter Ag Verfahren zur herstellung von fibrinogen und fibronectin sowie proteinzusammesetzungen, welche damit herstellbar sind
DE19923027C2 (de) * 1999-05-19 2002-09-19 Aventis Behring Gmbh Verfahren zur Inaktivierung von Viren
US6699465B2 (en) 2001-05-18 2004-03-02 Albany Medical College Covalent attachment of polymer to cell to prevent virus bonding to receptor
WO2003062375A2 (en) * 2001-12-19 2003-07-31 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
US8541399B2 (en) 2002-02-19 2013-09-24 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
US8450378B2 (en) * 2006-02-09 2013-05-28 Gojo Industries, Inc. Antiviral method
US8119115B2 (en) * 2006-02-09 2012-02-21 Gojo Industries, Inc. Antiviral method
US9629361B2 (en) 2006-02-09 2017-04-25 Gojo Industries, Inc. Composition and method for pre-surgical skin disinfection
JP5555626B2 (ja) 2007-08-13 2014-07-23 バクスター・インターナショナル・インコーポレイテッド 多発性硬化症、アルツハイマー病およびパーキンソン病を処置するためのケモカインのｉｖｉｇ調節
KR100900013B1 (ko) 2007-12-04 2009-05-29 씨제이제일제당 (주) 유체로부터 재조합 인간 에리스로포이에틴을 정제하는 방법
CA2742817A1 (en) * 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
DK2196090T3 (da) * 2008-12-12 2012-05-21 Oro Clean Chemie Ag Virucidt desinfektionsmiddel
NZ629867A (en) 2012-02-29 2016-09-30 Baxalta Inc Igg stimulated remyelination of peripheral nerves
CA2930687C (en) 2013-11-15 2024-04-23 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
MX2020004151A (es) * 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2232820A (en) * 1938-08-19 1941-02-25 Wood John Mfg Co Inc Switch and computer control for fluid dispensing pumps
US2303432A (en) * 1939-10-20 1942-12-01 Atlas Powder Co Shortening
US2232821A (en) * 1940-04-09 1941-02-25 Andrew A Barna Antiskidding device
US2380166A (en) * 1941-05-27 1945-07-10 Atlas Powder Co Emulsions
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
CA1101332A (fr) * 1976-01-30 1981-05-19 Edward Shanbrom Procedes simplifies pour la preparation de concentres de facteur viii de tres grande purete
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4412985A (en) * 1980-10-06 1983-11-01 Edward Shanbrom Depyrogenation process
DE3173208D1 (en) * 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
ATE36457T1 (de) * 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
US4764369A (en) * 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPH0662436B2 (ja) * 1986-05-19 1994-08-17 株式会社ミドリ十字 静注用免疫グロブリン製剤の製造方法
IL86417A (en) * 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
CA2006684C (en) * 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
ES2042138T3 (es) * 1989-05-24 1993-12-01 Miles Inc. Filtracion en gel del factor viii tratado termicamente.
EP0431129B1 (en) * 1989-06-15 1996-05-29 Rorer International (Overseas) Inc. Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
JP3145696B2 (ja) * 1990-10-05 2001-03-12 日本ケミカルリサーチ株式会社 分泌型免疫グロブリンａ製剤の製造法
AT408191B (de) * 1991-08-19 2001-09-25 Haemosan Erzeugung Pharmazeuti Verfahren zur inaktivierung von prionen
DE4434538C2 (de) * 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens

Also Published As

Publication number Publication date
FI961536A (fi) 1996-04-04
ATE211927T1 (de) 2002-02-15
EP0722344B1 (de) 2002-01-16
HU9600906D0 (en) 1996-05-28
US5770199A (en) 1998-06-23
CA2173625A1 (en) 1995-04-13
FI961536A0 (fi) 1996-04-04
HU218490B (hu) 2000-09-28
HRP940645A2 (en) 1996-12-31
JPH09503218A (ja) 1997-03-31
HUT75310A (en) 1997-05-28
WO1995009657A1 (de) 1995-04-13
EP0722344A1 (de) 1996-07-24
DK0722344T3 (da) 2002-03-18
CZ95296A3 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
ES2173923T3 (es) Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente.
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
PL325338A1 (en) Methods of and compositions for selectivel;y modifying nucleic acids
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
CA2034489A1 (en) Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
AU3698697A (en) Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
NO972475L (no) Ny antitrombotisk formulering, fremgangsmåte for dens fremstilling og anvendelse derav
PT1299130E (pt) Processo papa o tratamento e prevencao de doencas infecciosas
ATE261737T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
ATE179164T1 (de) Hiv-proteaseinhibitoren
ES2147200T3 (es) Uso de un veneno de himenopteros para la fabricacion de un medicamento para tratar infecciones por virus de adn.
YU57994A (sh) Postupak za inaktiviranje virusa u prisustvu polialkilenglikola i farmaceutski preparat dobijen tim postupkom
ATE206456T1 (de) Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
UA9672A (uk) Спосіб лікування деструктивних форм гострого панкреатиту
ATE165508T1 (de) Verwendung von 2-methylamino-2-phenylcyclohexanon zur behandlung von infektionen und zur immunmodulation
RU98117264A (ru) Способ инактивации вируса иммунодефицита человека и других вирусов в плазме крови человека с сохранением функциональной активности белков плазмы крови

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 722344

Country of ref document: ES